リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Mesenchymal stem/stromal cells generated from induced pluripotent stem cells are highly resistant to senescence」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Mesenchymal stem/stromal cells generated from induced pluripotent stem cells are highly resistant to senescence

Aoi, Tomonori Tanaka, Akihito Furuhashi, Kazuhiro Ikeya, Makoto Shimizu, Asuka Arioka, Yuko Kushima, Itaru Ozaki, Norio Maruyama, Shoichi 名古屋大学

2023.11

概要

Mesenchymal stem/stromal cells (MSCs) are stem cells that exhibit self-renewal and differentiation potential, defined by their osteogenic, chondrogenic, and adipogenic properties and
surface markers.1 MSCs exist in vivo in the bone marrow, adipose tissue, and umbilical cord.
The use of MSCs has attracted attention in the field of regenerative medicine owing to their
anti-inflammatory effects and tissue repair-enhancing effects via proliferation of progenitor cells,
angiogenesis, and anti-apoptotic effects. We have also demonstrated the therapeutic effects of
MSCs in nephritis and acute kidney injury.2-4
As advances in clinical applications of MSCs have progressed, several critical issues have
emerged. First, cellular senescence is a concern in the clinical application of MSCs, since it
has been reported in vitro that MSCs have a decreased proliferation rate5 and a decreased differentiation potential6 with further cell passaging. Second, cellular heterogeneity is a potential
bottleneck in ensuring sufficient cell numbers for therapy. MSCs exhibit different proliferative and
differentiation capacities depending on their source.7-9 As a possible solution to these problems,
MSCs can be generated from induced pluripotent stem cells (iPSCs).10-13 iPSC-derived MSCs
(iMSCs) are expected to represent a new source of MSCs based on the possibility of obtaining
a large amount of cells showing relatively high uniformity and low invasiveness in cell harvesting. Therefore, we investigated the characteristics of iMSCs. We determined whether cellular
senescence observed in normal MSCs is overcome in iMSCs since there are few studies that
evaluate cellular senescence. In the present study, we successfully demonstrated that iMSCs are
more resistant to cellular senescence than bone marrow-derived MSCs (BM-MSCs) by staining
cells with fluorescein di-b-D-galactopyranoside (FDG), which can quantitatively evaluate the
cellular senescence,14 after continuous passaging and analyzing cell proliferation potential and
cell morphology. ...

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1 Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal

cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317.

doi:10.1080/14653240600855905.

2 Furuhashi K, Tsuboi N, Shimizu A, et al. Serum-Starved Adipose-Derived Stromal Cells Ameliorate

Crescentic GN by Promoting Immunoregulatory Macrophages. J Am Soc Nephrol. 2013;24(4):587–603.

doi:10.1681/ASN.2012030264.

3 Katsuno T, Ozaki T, Saka Y, et al. Low serum cultured adipose tissue-derived stromal cells ameliorate acute

kidney injury in rats. Cell Transplant. 2013;22(2):287–297. doi:10.3727/096368912X655019.

4 Shimamura Y, Furuhashi K, Tanaka A, et al. Mesenchymal stem cells exert renoprotection via extracellular

vesicle-mediated modulation of M2 macrophages and spleen-kidney network. Commun Biol. 2022;5(1):753.

Nagoya J. Med. Sci. 85. 682–690, 2023

689

doi:10.18999/nagjms.85.4.682

Tomonori Aoi et al

doi:10.1038/s42003-022-03712-2.

Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals

rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells. 2004;22(5):675–682.

doi:10.1634/stemcells.22-5-675.

6 Yang YK, Ogando CR, Wang See C, Chang TY, Barabino GA. Changes in phenotype and differentiation

potential of human mesenchymal stem cells aging in vitro. Stem Cell Res Ther. 2018;9(1):131. doi:10.1186/

s13287-018-0876-3.

7 Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells derived from various

mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum. 2005;52(8):2521–2529.

doi:10.1002/art.21212.

8 Yoshimura H, Muneta T, Nimura A, Yokoyama A, Koga H, Sekiya I. Comparison of rat mesenchymal

stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle. Cell Tissue Res.

2007;327(3):449–462. doi:10.1007/s00441-006-0308-z.

9 Mushahary D, Spittler A, Kasper C, Weber V, Charwat V. Isolation, cultivation, and characterization of

human mesenchymal stem cells. Cytometry A. 2018;93(1):19–31. doi:10.1002/cyto.a.23242.

10 Kamiya D, Takenaka-Ninagawa N, Motoike S, et al. Induction of functional xeno-free MSCs from human

iPSCs via a neural crest cell lineage. NPJ Regen Med. 2022;7(1):47. doi:10.1038/s41536-022-00241-8.

11 Liu Y, Goldberg AJ, Dennis JE, Gronowicz GA, Kuhn LT. One-step derivation of mesenchymal stem cell

(MSC)-like cells from human pluripotent stem cells on a fibrillar collagen coating. PLoS One. 2012;7(3):

e33225. doi:10.1371/journal.pone.0033225.

12 Villa-Diaz LG, Brown SE, Liu Y, et al. Derivation of mesenchymal stem cells from human induced

pluripotent stem cells cultured on synthetic substrates. Stem Cells. 2012;30(6):1174–1181. doi:10.1002/

stem.1084.

13 Frobel J, Hemeda H, Lenz M, et al. Epigenetic rejuvenation of mesenchymal stromal cells derived from

induced pluripotent stem cells. Stem Cell Reports. 2014;3(3):414–422. doi:10.1016/j.stemcr.2014.07.003.

14 Yang NC, Hu ML. A fluorimetric method using fluorescein di-beta-D-galactopyranoside for quantifying the

senescence-associated beta-galactosidase activity in human foreskin fibroblast Hs68 cells. Anal Biochem.

2004;325(2):337–343. doi:10.1016/j.ab.2003.11.012.

15 Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol.

2000;28(8):875–884. doi:10.1016/s0301-472x(00)00482-3.

16 Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat

Biotechnol. 2014;32(3):252–260. doi:10.1038/nbt.2816.

17 Iwashima S, Ozaki T, Maruyama S, et al. Novel culture system of mesenchymal stromal cells from human

subcutaneous adipose tissue. Stem Cells Dev. 2009;18(4):533–543. doi:10.1089/scd.2008.0358.

References End

5 Nagoya J. Med. Sci. 85. 682–690, 2023

690

doi:10.18999/nagjms.85.4.682

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る